Frovocimab
- CAS No.
- 1643672-70-1
- Chemical Name:
- Frovocimab
- Synonyms
- Frovocimab;Frovocimab (anti-PCSK9);Research Grade Frovocimab;Research Grade Frovocimab(DHJ24003)
- CBNumber:
- CB78081101
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
- TDS File:
- TDS
| FDA UNII | 87PZ955YRB |
|---|
Frovocimab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0628738 | Frovocimab 96.78% | 1643672-70-1 | 1mg | $433 | 2026-06-04 | Buy |
| ChemScene | CS-0628738 | Frovocimab 96.78% | 1643672-70-1 | 5mg | $1137 | 2026-06-04 | Buy |
| ChemScene | CS-0628738 | Frovocimab 96.78% | 1643672-70-1 | 10mg | $1571 | 2026-06-04 | Buy |
| aablocks | AA02DJL7 | Frovocimab ≥95%(SDS-PAGE&SEC-HPLC) | 1643672-70-1 | 1mg | $664 | 2026-06-03 | Buy |
| aablocks | AA02DJL7 | Frovocimab ≥95%(SDS-PAGE&SEC-HPLC) | 1643672-70-1 | 5mg | $2000 | 2026-06-03 | Buy |
Frovocimab Chemical Properties, Uses, Production
Uses
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9[1].
in vivo
Frovocimab (LY 3015014; 10 mg/kg; i.v; once) causes significant PCSK9 accumulation, its duration of LDL lowering is reduced, and its clearance (CL) from serum is accelerated in mice expressing a noncleavable variant of human PCSK9[1].
Frovocimab (LY 3015014; 5 mg/kg; i.v; once) decreases LDL cholesterol in monkeys and, unlike other PCSK9 mAbs, does not cause an accumulation of intact PCSK9 in serum[1].
| Animal Model: | Male C57BL/6NTac mice injected with vector containing the NC R215A/R218A variant[1] |
| Dosage: | 10 mg/kg |
| Administration: | i.v; once |
| Result: | Caused significant PCSK9 accumulation. |
| Animal Model: | Cynomolgus monkeys[1] |
| Dosage: | 5 mg/kg |
| Administration: | i.v; once |
| Result: | Decreased LDL cholesterol in monkeys. |
References
[1] Krista M Schroeder, et al. Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody. J Lipid Res. 2015 Nov;56(11):2124-32. DOI:10.1194/jlr.M061903
Frovocimab Preparation Products And Raw materials
Raw materials
Preparation Products
Frovocimab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| Wuhan Acumen Bio-Technology Co.,ltd | 027-027-16602739303 16602739303 | 673003916@qq.com | China | 4593 | 58 |
